Medicxi, the European life sciences investment firm, has appointed two US executives, Sanford Zweifach and Paul Sekhri, as venture partners to lead development of the fund’s portfolio companies. Mr Zweifach is chairman of Palladio Biosciences Inc, a developer of drugs for orphan diseases of the kidney, as well as co-founder and advisor to Nuvelution Pharma Inc. Mr Sekhri is the chief executive of eGenesis, a genome editing company. Both executives have years of experience in business development and capital raising. Mr Zweifach was previously managing director of Bay City Capital where he led the firm’s merger and acquisition activity, while Mr Sekhri held senior commercial positions at Novartis.
Mr Zweifach received a BA in biology from the University of California, San Diego while Mr Sekhri earned a BS in zoology from the University of Maryland, College Park, both in the US.
Medicxi announced the appointments on 17 March 2020.
(Editor's note: The date of the announcement has been corrected to read 17 March instead of 18 March).
Copyright 2020 Evernow Publishing Ltd.